BriaCell Therapeutics (Nasdaq: BCTX, BCTXZ) (TSX: BCT) announced the pricing of an underwritten public offering of 3,066,666 units at $4.50 per unit for gross proceeds of approximately $13.8 million. Each unit includes one common share or pre-funded warrant and one warrant exercisable at $5.25 per share. The offering, led by ThinkEquity, is expected to close on April 28, 2025, subject to customary conditions. BriaCell plans to use the net proceeds for working capital, corporate purposes and advancing business objectives.
To view the full article, visit https://ibn.fm/745T0
About BriaCell Therapeutics
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.
For more information, visit the company’s website at https://briacell.com/
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN